Press Release Archive

(BUSINESS WIRE)--Pfizer Inc invites investors, media, and the general public to view and listen to a webcast of a presentation by Pfizer’s neuroscience leadership team at an analyst and investor meeting on Monday, July 28, at 6:00 p.m. Central Daylight Saving Time, in connection with the annual meeting of the International Conference on Alzheimer’s Disease (ICAD). To view and listen to the webcast, visit our web site

(BUSINESS WIRE)--Pfizer Inc announced today that it has entered into an agreement with generics manufacturer Ranbaxy Laboratories Ltd. of India and certain of its affiliates to settle substantially all their patent litigation worldwide involving Lipitor, the world’s most-prescribed cholesterol-lowering medicine. Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Lipitor and Caduet in the United

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it has entered into a $15-million dollar collaboration with the University of Pennsylvania School of Medicine. The partnership will include collaborations between Pfizer and the University in the areas of scientific research, clinical development and clinical care and policy. Under the terms of the agreement, Pfizer will pay Penn $15 million over a three-year period, during

(BUSINESS WIRE)--In a novel experiment to advance new drug discovery and development, as well as stimulate basic research, Pfizer, Inc. and UCSF have launched a collaboration that spans many disciplines, several UC campuses and multiple Pfizer research units. The three year agreement, with research and other support up to $9.5 million, establishes a university team to help identify promising areas of mutual interest and facilitate

(BUSINESS WIRE)--Pfizer Inc today announced that Charles E. Triano will join the company as Senior Vice President, Investor Relations, effective June 23. Mr. Triano, who will be responsible for all investor relations functions, including communicating the financial and operational performance of the company with institutional and retail investors, will report directly to Chief Financial Officer Frank D’Amelio. Since 2000

(BUSINESS WIRE)--Pfizer Inc announced today as part of its commitment to oncology that it expects to start a total of seven Phase 3 studies in 2008; two are open and enrolling, and five are planned to begin by the end of 2008. These trials involve three different compounds: Sutent, axitinib and CP-751,871, and will focus on 4 types of cancers – hepatocelluar (HCC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and

(BUSINESS WIRE)--AVANT Immunotherapeutics (Nasdaq: AVAN) and Pfizer, Inc. (NYSE: PFE) today announced the presentation of new data from two Phase 2 studies at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) for CDX-110, an investigational immunotherapeutic vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII). CDX-110 was generally well-tolerated with primary

(BUSINESS WIRE)--Pfizer Inc today named Amy W. Schulman as Senior Vice President and General Counsel, effective June 23. In her new role, Ms. Schulman will be responsible for leading Pfizer’s legal division. She will serve on the company’s Executive Leadership Team (ELT) and will report directly to Chairman and Chief Executive Officer Jeffrey B. Kindler. Ms. Schulman joins Pfizer from DLA Piper, where she was a partner

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts and institutional investors to be held on Monday, June 2, at 6:00 p.m. Central Daylight Saving Time, in connection with the annual meeting of the American Society of Clinical Oncology (ASCO). The analyst and investor meeting will include presentations by Pfizer’s oncology leadership team